Studies have indicated that compared to non-squamous cell carcinoma, lung squamous cell carcinoma exhibits higher PD-L1 expression, higher tumor mutational burden (TMB), and a greater density of functional TILs in the tumor microenvironment, factors that collectively contribute to the enhanced therapeutic effects of immunotherapy in squamous cell carcinoma patients (28). This evidence concerns the gene CD274 and neoplasm.